Capital Investment to Improve Productivity and Strengthen Research and Development
First written in FY2016. 9 of 21 entries say "Restated". Latest entry: FY2026.
Nippi moved to the "Worse" side of this theme in 2022.
The whole theme swung hardest in 2025: 3 of 15 companies on the "Worse" side.
1 other company's latest entry also says "Restated".
- FY2026RestatedAnnual report
「During the current consolidated fiscal year, we continued to make capital investments aimed at improving productivity and strengthening research and development. Capital investment, measured on an acquisition basis for tangible and intangible fixed assets, totaled ¥618 million. …」
Facility upgrades aimed at improving productivity and strengthening research and development continued, and capital investment totaled ¥618 million. No plans for the disposal or construction of major facilities were presented. - FY2025SoftenedAnnual report
「Capital investment, measured on an acquisition basis for tangible and intangible fixed assets, totaled ¥495 million. … During the current consolidated fiscal year, there were no disposals of major facilities other than disposals related to routine facility replacements.」
Facility upgrades to improve productivity and strengthen research and development continued, but capital investment declined to ¥495 million from ¥1,562 million in the previous fiscal year, and no plans for major new facilities or disposals were presented. - FY2024AdvancedAnnual report
「Capital investment, measured on an acquisition basis for tangible and intangible fixed assets, totaled ¥1,562 million. Capital investment by segment was as follows.」
Capital investment increased to ¥1,562 million from ¥266 million in the previous fiscal year, including ¥1,272 million invested in improvements and upgrades to manufacturing facilities in the collagen and casing business. - FY2023SoftenedAnnual report
「Capital investment, measured on an acquisition basis for tangible and intangible fixed assets, totaled ¥266 million. Capital investment by segment was as follows.」
Facility upgrades aimed at improving productivity and strengthening research and development continued, but capital investment declined to ¥266 million from ¥460 million in the previous fiscal year, and no plans for major new facilities were presented. - FY2022SoftenedAnnual report
「Capital investment, measured on an acquisition basis for tangible and intangible fixed assets, totaled ¥460 million. Capital investment by segment was as follows.」
Capital investment to improve productivity and strengthen research and development continued, but investment declined to ¥460 million from ¥3,413 million in the previous fiscal year, and no major plans for new facilities were presented. - FY2021RestatedAnnual report
「During the current consolidated fiscal year, we continued to make capital investments aimed at improving productivity and strengthening research and development. Capital investment totaled ¥3,413 million.」
Capital investment aimed at improving productivity and strengthening research and development continued, and capital investment during the current period totaled ¥3,413 million. - FY2020RestatedAnnual report
「In addition to constructing a new collagen peptide plant in Fujinomiya, Shizuoka Prefecture, which began operations in August 2019, we made capital investments primarily to replace machinery and equipment that is routinely replaced. Capital investment totaled ¥3,701 million.」
It was confirmed that ¥3,701 million was invested in the gelatin-related business, based on the completion and start of operations of the new collagen peptide plant. - FY2020-Q2AchievedAnnual report
「The major facilities that had been under consideration in the previous consolidated fiscal year and were completed during the cumulative second quarter of the current consolidated fiscal year were as follows: ㈱ニッピ, Fujinomiya, Shizuoka Prefecture, gelatin-related business, collagen peptide manufacturing plant, total investment of ¥3,275 million, completed August 2019.」
The collagen peptide manufacturing plant, representing total investment of ¥3,275 million, was completed and began operations in August 2019. - FY2020-Q1RestatedAnnual report
「There were no significant changes during the cumulative first quarter of the current consolidated fiscal year to the planned construction, suspension, major refurbishment, disposal or sale of major facilities that had been under consideration in the previous consolidated fiscal year.」
It was stated that there were no significant changes to the plans for major facilities. - FY2019AdvancedAnnual report
「Of the approximately ¥3,180 million in construction funding for the collagen peptide plant scheduled to begin operations around summer 2019, ¥2,683 million had already been spent. We expect to fund future payments for capital expenditures through operating cash flow and borrowings from financial institutions.」
Against the collagen peptide plant's planned start of operations around summer 2019, ¥2.683 billion of the approximately ¥3.18 billion in construction funding had already been spent, indicating progress on the project. - FY2019-Q3AdvancedAnnual report
「This was mainly due to a ¥2,442 million increase in construction in progress associated with construction of the collagen peptide manufacturing plant and other facilities, a ¥1,102 million decrease in cash and deposits, and a ¥909 million decrease in merchandise and finished goods.」
Construction of the collagen peptide manufacturing plant progressed, increasing construction in progress by ¥2,442 million. - FY2019-Q2RestatedAnnual report
「There were no significant changes during the cumulative second quarter of the current consolidated fiscal year to the planned construction, suspension, major refurbishment, disposal or sale of major facilities that had been under consideration in the previous consolidated fiscal year.」
It was stated that there were no significant changes to the plans for major facilities. Construction of the collagen peptide manufacturing plant was continuing, and construction in progress was increasing. - FY2019-Q1AdvancedAnnual report
「Total assets at the end of the first quarter of the current consolidated fiscal year were ¥69,872 million, an increase of ¥1,287 million from the end of the previous consolidated fiscal year. This was mainly due to an increase in construction in progress related to the collagen peptide manufacturing plant under construction.」
Construction in progress related to the collagen peptide manufacturing plant under construction increased, resulting in a ¥1,287 million increase in total assets from the end of the previous consolidated fiscal year. - FY2018AdvancedAnnual report
「Construction funding of approximately ¥3,300 million for the collagen peptide plant scheduled for completion in March 2019 had already included ¥15 million in expenditure. We expect to fund future payments for capital expenditures through operating cash flow and borrowings from financial institutions.」
For the collagen peptide manufacturing plant, ¥15 million had already been spent against the plan for approximately ¥3.3 billion in investment, with completion scheduled for March 2019. - FY2018-Q3AdvancedAnnual report
「(New construction) Fuji Plant (Fujinomiya, Shizuoka Prefecture) Gelatin-related business Collagen peptide manufacturing equipment Planned investment: ¥3,300 million Internal funds and borrowings Construction commenced January 2018 Scheduled completion March 2019」
A new construction plan for collagen peptide manufacturing equipment in the gelatin-related business was finalized, with planned investment of ¥3.3 billion, construction commencing in January 2018 and completion scheduled for March 2019. - FY2018-Q2RestatedAnnual report
「During the cumulative second quarter of the consolidated fiscal year under review, there were no significant changes in major facilities or significant changes to the plans as of the end of the previous consolidated fiscal year.」
It was reconfirmed that there were no significant changes or revisions to the plans for major facilities as of the end of the previous fiscal year. - FY2017SoftenedAnnual report
「During the current consolidated fiscal year, we continued to make capital investments aimed at improving productivity and strengthening research and development. Capital investment totaled ¥638 million and was funded by borrowings and internal funds. There are no plans to construct any major new facilities.」
Capital investment to improve productivity and strengthen research and development continued, but investment declined to ¥638 million from ¥5,110 million in the previous fiscal year. Following the major investment in the Fujinomiya No. 2 Plant, no major plans for new facilities were identified. - FY2017-Q3RestatedAnnual report
「During the cumulative third quarter of the consolidated fiscal year under review, there were no significant changes in major facilities or significant changes to the plans as of the end of the previous consolidated fiscal year.」
It was reconfirmed that there were no significant changes or plan revisions concerning the construction, suspension, major refurbishment, disposal or sale of major facilities. - FY2017-Q2RestatedAnnual report
「During the cumulative second quarter of the consolidated fiscal year under review, there were no significant changes in major facilities or significant changes to the plans as of the end of the previous consolidated fiscal year.」
It was reconfirmed that there were no significant changes to plans for the construction, suspension, major refurbishment, disposal or sale of major facilities. - FY2017-Q1RestatedAnnual report
「There were no significant changes during the cumulative first quarter of the current consolidated fiscal year to the planned construction, suspension, major refurbishment, disposal or sale of major facilities that had been under consideration in the previous consolidated fiscal year.」
It was confirmed that there were no significant changes to the major capital investment plans. - FY2016First statedAnnual report
「During the current consolidated fiscal year, we continued to make capital investments aimed at improving productivity and strengthening research and development in each segment, in addition to constructing a new collagen casing plant.」
Capital investment during the current consolidated fiscal year totaled ¥5,110 million, of which ¥4,798 million was attributable to the collagen and casing business.